New biomarkers in kidney transplant

Maurizio Salvadori; Giuseppina Rosso

doi:10.33393/gcnd.2024.3352

Authors

Maurizio Salvadori Professore di Nefrologia già Direttore Nefrologia e Trapianto, Azienda Ospedaliero-Universitaria Careggi , Firenze - Italy https://orcid.org/0000-0003-1503-2681
Giuseppina Rosso Azienda Usl Toscana Centro, S.O.C. Nefrologia e Dialisi, Firenze 1 ed Empoli, Nuovo Ospedale San Giovanni di Dio , Firenze - Italy

DOI:

https://doi.org/10.33393/gcnd.2024.3352

Keywords:

Acute kidney rejection, Biomarkers, Donor-derived cell-free DNA, Gene expression profiling, Subclinical rejection, Urinary cytokines

Abstract

Recently, new interesting and important novel biomarkers have allowed the evidence based medicine to move to a new field called precision medicine. In particular, this apply to organ transplantation and to the diagnosis of rejection.

Among these novel biomarkers are the study of donor-derived cell-free DNA when present in the blood of the recipients, the study of gene expression profiling again in the recipient, and the study of several urinary cytokines. All these novel biomarkers have several advantages over the old biomarkers. Indeed, they are non-invasive, are able to detect renal damage before the appearance of histological abnormalities, and are able to distinguish antibody-mediated rejection from cell-mediated rejection. The aim of this study is to identify the most recent findings on these biomarkers and to describe their utility and their limitations in particular in the field of kidney acute rejection.

Downloads

Download data is not yet available.

References

Anglicheau D, Naesens M, Essig M, Gwinner W, Marquet P. Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches. Transplantation. 2016;100(10):2024-2038. https://doi.org/10.1097/TP.0000000000001321 PMID:27479159

Gielis EM, Ledeganck KJ, De Winter BY, et al. Cell-Free DNA: An Upcoming Biomarker in Transplantation. Am J Transplant. 2015;15(10):2541-2551. https://doi.org/10.1111/ajt.13387 PMID:26184824

Graver AS, Lee D, Power DA, Whitlam JB. Understanding Donor-derived Cell-free DNA in Kidney Transplantation: An Overview and Case-based Guide for Clinicians. Transplantation. 2023;107(8):1675-1686. https://doi.org/10.1097/TP.0000000000004482 PMID:36579675

Wijtvliet VPWM, Plaeke P, Abrams S, et al. Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis. Transpl Int. 2020;33(12):1626-1642. https://doi.org/10.1111/tri.13753 PMID:32981117

Xiao H, Gao F, Pang Q, et al. Diagnostic Accuracy of Donor-derived Cell-free DNA in Renal-allograft Rejection: A Meta-analysis. Transplantation. 2021;105(6):1303-1310. https://doi.org/10.1097/TP.0000000000003443 PMID:32890130

Lefaucheur C, Loupy A. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med. 2018;379(26):2580-2582. PMID:30586534

Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307. https://doi.org/10.1111/ajt.14625 PMID:29243394

Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. Am J Transplant. 2020;20(9):2491-2498. https://doi.org/10.1111/ajt.15822 PMID:32056331

Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011;35:359-364. PMID:22755431

Bu L, Gupta G, Pai A, et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int. 2022;101(4):793-803. https://doi.org/10.1016/j.kint.2021.11.034 PMID:34953773

Suthanthiran M, Schwartz JE, Ding R, et al; Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. Transplantation. 2012;93:1136-1146.

Hricik DE, Nickerson P, Formica RN, et al; CTOT-01 consortium. Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant. 2013;13(10):2634-2644. https://doi.org/10.1111/ajt.12426 PMID:23968332

Friedewald JJ, Kurian SM, Heilman RL, et al; Clinical Trials in Organ Transplantation 08 (CTOT-08). Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant. Am J Transplant. 2019;19(1):98-109. https://doi.org/10.1111/ajt.15011 PMID:29985559

Zhang W, Yi Z, Keung KL, et al. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. J Am Soc Nephrol. 2019;30(8):1481-1494. https://doi.org/10.1681/ASN.2018111098 PMID:31278196

Marsh CL, Kurian SM, Rice JC, et al. Application of TruGraf v1: A Novel Molecular Biomarker for Managing Kidney Transplant Recipients With Stable Renal Function. Transplant Proc. 2019;51(3):722-728. https://doi.org/10.1016/j.transproceed.2019.01.054 PMID:30979456

Heilman RL, Fleming JN, Mai M, et al. Multiple abnormal peripheral blood gene expression assay results are correlated with subsequent graft loss after kidney transplantation. Clin Transplant. 2023;37(8):e14987. https://doi.org/10.1111/ctr.14987 PMID:37026820

Park S, Guo K, Heilman RL, et al. Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2021;16(10):1539-1551. https://doi.org/10.2215/CJN.05530421 PMID:34620649

Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med. 2001;344(13):947-954. https://doi.org/10.1056/NEJM200103293441301 PMID:11274620

Suthanthiran M, Schwartz JE, Ding R, et al; Clinical Trials in Organ Transplantation 04 (CTOT-04) Study Investigators. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med. 2013;369(1):20-31. https://doi.org/10.1056/NEJMoa1215555 PMID:23822777

Ho J, Wiebe C, Gibson IW, Rush DN, Nickerson PW. Immune monitoring of kidney allografts. Am J Kidney Dis. 2012;60(4):629-640. https://doi.org/10.1053/j.ajkd.2012.01.028 PMID:22542291

Tinel C, Devresse A, Vermorel A, et al. Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. Am J Transplant. 2020;20(12):3462-3476. https://doi.org/10.1111/ajt.15959 PMID:32342614

Hirt-Minkowski P, Handschin J, Stampf S, et al. Randomized Trial to Assess the Clinical Utility of Renal Allograft Monitoring by Urine CXCL10 Chemokine. J Am Soc Nephrol. 2023;34(8):1456-1469. https://doi.org/10.1681/ASN.0000000000000160 PMID:37228005